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httpObjectives: The aim of this study was to compare externally supported thin wall knitted polyester (P-EXS) and
externally unsupported thin wall knitted polyester (P-non-EXS) for above-knee (AK) femoro-popliteal bypass
grafting.
Design: A prospective multicenter randomised clinical trial.
Material and methods: Between 1999 and 2008, 265 AK femoro-popliteal bypass grafts (6 mm in diameter) were
performed, including 136 P-EXS and 129 P-non-EXS. The selection of patients was based on the presence of
disabling claudication or critical ischaemia. Follow-up took place at 3, 6, 12, 18, and 24 months and included
clinical examination and duplex ultrasonography. The main end points of this study were primary patency rates at
one and two years. Secondary end points were mortality, and primary assisted and secondary patency rates.
Cumulative patency rates were calculated with life-table analysis and log-rank testing.
Results: The 1-year primary, primary assisted and secondary patency rates were 65%, 70% and 84%, respectively, for
P-EXS and 76% (p¼ 0.05), 82% (p¼ 0.03) and 88% (p¼ 0.35), respectively, for P-non-EXS.Two-year primary, primary
assisted and secondary patency rates were 45%, 57% and 70%, respectively, for P-EXS and 62% (p ¼ 0.003), 75%
(p ¼ 0.005) and 84% (p ¼ 0.02), respectively, for P-non-EXS. The overall mortality rate after two years was 11.3%.
Conclusion: In above-knee femoro-popliteal bypass grafting patency rates of externally supported knitted
polyester grafts were inferior to their unsupported counterpart.
ISRCTN: At the time this study started this number was not the standard.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Above-knee (AK) femoro-popliteal bypass grafting is an
effective treatment for either disabling claudication or
critical ischaemia. Although autologous grafts are preferred,
prosthetic material is still frequently used due to absence of
these venous conduits.1e3
Literature on this topic shows many factors that could
have an impact on graft patency.
In a previous study we showed that the outcome of
polyester AK femoro-popliteal bypass grafting is nearly as
good as venous conduit under the condition of an intact
crural outﬂow.4
Another possible factor inﬂuencing the patency is the
structure of the graft and its inﬂuence on kinking and
compression in hip and knee ﬂexion. Kinking is widelyrresponding author. Tel.: þ31 53 8742510; fax: þ31 53 4872526.
il address: r.geelkerken@mst.nl (R.H. Geelkerken).
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://dx.doi.org/10.1016/j.ejvs.2012.11.032described in below-knee (BK) bypass grafts.5,6 However, it is
also reported in AK femoro-popliteal bypass grafts.7 According
to El-Massry et al., ﬂexion of the knee could rotate the tibia
extensively in posterior direction in relation to the femoral
condyles. As a consequence, the AK popliteal arterymaymove
upwards. The supported graft could possibly compensate the
reduced distance by adopting a S-shaped conﬁguration which
is the only conformational change allowed by the support
coil.5 External support should enable use of a non-crimped
graft without the danger of kinking in the femoro-popliteal
position.6,8 Obviously, kinking of the prosthesis inﬂuences the
haemodynamic ﬂow state of the vessel and therefore the
patency. However, this hypothesis remains unconﬁrmed. The
aim of this study was to compare the effects on patency
of externally supported thin wall knitted polyester (P-EXS)
and externally unsupported thin wall knitted polyester
(P-non-EXS) for AK femoro-popliteal bypass grafting.
PATIENTS AND METHODS
In this multicenter randomised trial patients were included
from September 1999 until August 2008. For this analysis all
Table 1. Participating hospitals.
Hospital P-EXS
(n)
P-non-EXS
(n)
Total
(n)
Medisch Spectrum Twente
Hospital, Enschede
73 69 142
Maastricht University Medical
Centre, Maastricht
23 27 50
Twenteborg Hospital, Almelo 20 15 35
General Hospital
Midden-Twente, Hengelo
10 10 20
Jeroen Bosch Hospital, Den
Bosch
9 7 16
Deventer Hospital, Deventer 1 1 2
Table 2. Pre-operative patient characteristics.
Parameter P-EXS
n(%)
P-non-EXS
n(%)
p-value
Gender M/F 103/33 96/33 0.80
Age (y) mean (range) 65(39e84) 67(47e85) 0.14
Co-morbidity (%)
DM 38(27.9) 33(25.6) 0.67
Hypertension 67(49.3) 67(51.9) 0.66
Hypercholesterolaemia 65(47.8) 68(52.7) 0.42
Cerebrovascular disease 15(11.0) 14(10.9) 0.96
Cardiac disease 51(37.5) 40(31.0) 0.27
Smoking 0.25
Never 31(22.8) 29(22.5)
Quit 38(27.9) 40(31.0)
<20/day 51(37.5) 36(27.9)
>20/day 16(11.8) 24(18.6)
Anticoagulant therapy
Coumarin 21(15.4) 24(18.6) 0.49
Acetyl salicylic acid 94(69.1) 89(69.0) 0.98
Ischaemia category 0.10
Rutherford classiﬁcation
1 (Mild claudication) 8(5.9) 1(0.8)
2 (Moderate claudication) 29(21.3) 31(24.0)
3 (Severe claudication) 47(34.6) 54(41.9)
4 (Rest pain) 22(16.2) 17(13.2)
5 (Minor tissue loss) 30(22.1) 24(18.6)
6 (Major tissue loss) 0(0.0) 2(1.6)
No. patent crural vessels 0.71
0 8(5.9) 9(7.0)
1 35(25.7) 37(28.7)
2 45(33.1) 46(35.7)
3 48(35.3) 37(28.7)
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protocol of this study followed the principles stated in the
Declaration of Helsinki and the Consolidated Standards of
Reporting Trials (CONSORT).9 Furthermore, the Institutional
Review Boards of all participating hospitals approved the
study and informed consent was obtained from all patients.
All patients who required an AK femoro-popliteal bypass
for disabling claudication, rest pain or tissue loss, and in the
absence of suitable venous conduit, were eligible for this trial.
Criteria for exclusion were previous ipsilateral femoro-
popliteal procedures, contra-indication for the use of acetyl
salicylic acid or anticoagulants, patients receiving chemo- or
radiotherapy, malignancy diagnosed or treated within 12
months, known allergy to iodine or contrast medium, and
impaired renal function.
Demographic and risk factors were according to The
Society for Vascular SurgeryeInternational Society for
Cardiovascular Surgery (SVS-ISCVS) risk score,10 including
patient history, physical examination and ankleebrachial
index (ABI). Anatomical evaluation was performed with
Digital Subtraction Angiography (DSA). The outﬂow was
scored in the number of patent crural vessels. If the vessel
was less than 50% stenosed, it was scored as a patent vessel.
Randomisation was done per centre with block size of 4.
Patients were selected by means of a sealed envelope at
the day of surgery in the operating theatre after inspection
of the quality of the proximal and distal anastomotic sites.
Operations were performed by vascular surgeons under
general or regional anaesthesia and all patients received
antibiotic prophylaxis according to local guidelines. Intra-
operatively, 5000 units of heparin were administered
intravenously before clamping. The grafts applied were
either a 6-mm externally supported thin wall ﬂuoropolymer
coated knitted polyester (P-EXS) or a 6-mm externally
unsupported thin wall knitted polyester (P-non-EXS) (both
Fluoropassiv, Sulzer Vascutek, Inchinnan Renfrewshire,
Scotland, United Kingdom). The prosthesis was placed in an
anatomical or sub-sartorial position and in the P-EXS graft
the supported coil was removed 5 mm to the anastomotic
heal. The anastomoses were performed end-to-side with
Prolene 6/0 (Johnson & Johnson, Ethicon, Norderstedt,
Germany) proximal onto the common femoral artery and
distal onto the AK popliteal artery.
In each participating centre, patients received thrombotic
prophylaxis (Low Molecular Weight Heparin) and acetyl sal-
icylic acid post-operatively, unless there was an indication for
another form of anticoagulant therapy. Follow-up assess-
ments were done at 3, 6, 12, 18, and 24 months. Graft
patency was evaluated through palpation of pulses, anklee
brachial index measurements and duplex examination.
The main end points of this study were primary patency
rates at one and two years. Secondary end points were
mortality, primary assisted and secondary patency rates.
In accordance with the (SVS-ISCVS) guidelines, primary
patency was deﬁned as uninterrupted patency without any
manipulation of the graft. Primary assisted patency was
deﬁned as uninterrupted graft patency, but maintained by
prophylactic intervention such as angioplasty. Secondarypatency was deﬁned as restored patency after occlusion
with or without revision of the graft.10
STATISTICS
The hypothesis tested was a 20% improvement in primary
patency for the P-EXS cohort, from 60% to 80%. The study
needed at least 108 patients in each group to obtain 90%
statistical power with a ¼ 0.05. It was decided to include
two groups of 135 patients each to compensate for loss to
follow-up. Potential differences in categorical demographic
and risk factors between the two groups were analysed by
Pearson Chi Square test, or Fisher’s Exact test, as appro-
priate. Calculation of patency rates was done with the life
B.H.R. Vriens et al. 277table method, compared with a log-rank test and the results
are displayed in KaplaneMeier graphs. A p-value of <0.05
was considered to be signiﬁcant.RESULTS
Baseline characteristics
In total 266 patients were randomised for an AK femoro-
popliteal bypass with P-EXS or P-non-EXS. One person did
not receive the allocated intervention, leaving 265 patients
(136 for P-EXS and 129 P-non-EXS) from six hospitals in the
Netherlands for further analysis (Table 1). Fourteen patients
have received a second procedure with one of the study
prosthesis on the contralateral leg, however, these second
procedures have been excluded from the analysis.
The group which was further analysed consisted of 199
(75%) male and 66 (25%) female patients. Patient demo-
graphic and risk factors were similar in both groups (Table 2).
Patients who participated were distributed between
disabling claudication 64% (n ¼ 170), rest pain 15%Assessed for elig
Analysed (n=136) 
- Excluded from analysis (n=0) 
Lost to follow-up  
- Incomplete follow-up (n=4) 
Discontinued follow-up (n=17) 
- Death: 15 
- Graft Removal: 2 
Allocated to P-EXS (n=136) 
- Received allocated intervention (n= 136) 
- Did not receive allocated intervention (n=0) 
Allocati
Analys
Follow-
Randomized
Enrollment 
Figure 1. CONSORT-ﬂowchart o(n ¼ 39), and tissue loss 21% (n ¼ 56). Nineteen percent of
the patients with critical ischaemia had inﬂow disease and
49% had outﬂow disease.Operative details
Eighty-six bypass grafts (32%) were performed under general
anaesthesia, the remaining bypasses under spinal or epidural
anaesthesia. Intra-operatively 5000 units of heparin was
administered during 259 procedures (98%). In 3 procedures,
3000 units of heparin was administered because of extensive
bleeding, and in another threeprocedures a total of 7500units
was administered, because of a longer operation time.Follow-up
Within 2 years of follow-up only 4 (1.5%) patients were lost.
All other subjects had a follow-up of at least 2 years. Thirty
days mortality rate was 0.8% (one patient with a P-EXS and
one with a P-non-EXS bypass graft). Both patients died
within the hospital. Within 2 years follow-up, 30 (11.3%) ofibility (n=267) 
Excluded (n=1) 
- Not meeting inclusion criteria (n=1) 
- Declined to participate (n=0) 
- Other reasons (n= 0) 
on
is 
Up 
 (n=266)
Allocated to P-non-EXS (n=130) 
- Received allocated intervention (n=129) 
- Did not receive allocated intervention (n=1) 
Lost to follow-up  
- Incomplete follow-up (n=0) 
Discontinued follow-up (n=16) 
- Death: 15 
- Graft Removal: 1 
Analysed (n=129) 
- Excluded from analysis (n=0) 
f participants in the study.
Figure 3. KaplaneMeier curves of primary assisted patency rates
for P-EXS (57%) and P-non-EXS (75%) (p ¼ 0.005). The Standard
error did not exceed 10% up to 24 months.
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the P-non-EXS group (Fig. 1). At the time of death, 23 (77%)
of these patients had a primary patent bypass, 3 had
a primary assisted patent and 2 had a secondary patent
bypass. Two patients had an occluded bypass.
Within 2 years follow-up, 54 grafts occluded, including 33
P-EXS (61%) and 21 P-non-EXS (39%). Additional procedures
during follow-up were done in 66% of the patients with
critical ischaemia (Rutherford 4e6). Sixteen patients
received an amputation of which 3 major amputations.
Seventeen patients received a thrombectomy, 3 patients
thrombolysis treatment, and 12 patients needed a new
bypass. In 10 patients the anastomosis had to be revised
and 5 patients underwent angioplasty. Within the 2 years
reporting period 3 (1.1%) grafts, 2 P-EXS and 1 P-non-EXS,
had been removed because of an infection.
The 1-year primary, primary assisted and secondary
patency rates were respectively 65%, 70% and 84% for P-
EXS and 76% (p ¼ 0.05), 82% (p ¼ 0.03) and 88% (p ¼ 0.35)
for P-non-EXS.
The 2-year primary, primary assisted and secondary
patency rates were respectively 45%, 57% and 70% for P-
EXS and 62% (p ¼ 0.003), 75% (p ¼ 0.005) and 84%
(p ¼ 0.02) for P-non-EXS (Figs. 2e4).
DISCUSSION
The present study has failed to show any beneﬁcial effect of
P-EXS for AK femoro-popliteal bypass grafts. Surprisingly,
the results were in the opposite direction. Patency rates of
P-EXS grafts at one and two year follow-up were lower than
for P-non-EXS grafts. The concept of external support has
primarily been proposed to avoid kinking in areas of highFigure 2. KaplaneMeier curves of primary patency rates for P-EXS
(45%) and P-non-EXS (62%) (p ¼ 0.003). The Standard error did not
exceed 10% up to 24 months.mobility such as in the knee area, and to avoid external
compression in areas where the bypass is placed subcuta-
neously, such as for axillo-(bi)femoral bypass.11e17 Although
the use of an externally supported femoro-popliteal graft
was ﬁrst described in the 1980s, a randomised controlledFigure 4. KaplaneMeier curves of secondary patency rates for
P-EXS (70%) and P-non-EXS (84%) (p ¼ 0.02). The Standard error
did not exceed 10% up to 24 months.
B.H.R. Vriens et al. 279trial comparing externally supported with unsupported
polyester for AK femoro-popliteal bypass grafting had never
been conducted before.6
Several reports described patency results of externally
supported prostheses for AK femoro-popliteal bypass
grafts.5,6,8,14e18 El-Massry et al. reported in a retrospective
analysis of 200 externally supported polyester femoro-
popliteal bypass grafts 3, 5 and 10-year primary patency
rates of 76%, 71% and 50%, respectively.5 The ﬁrst trial
comparing externally supported polyester with unsupported
polyester for AK bypass grafting reported 4-year primary
patency results of 78% and 56%, respectively.8 A recent
retrospective report showed after 8 years even signiﬁcantly
better results of the externally supported non-coated knitted
polyester compared to gelatin-coated polyester.15
It is striking that our study with P-EXS showed such
disappointing patency results compared to other trials with
externally supported prostheses. However, all these studies
used different types of supported prostheses. Moreover,
67% of subjects had only one or two patent crural vessels,
accounting for a population with a rather poor outﬂow.
Only one prospective non-randomised German trial used
the same externally supported polyester prosthesis as we
did. Although the results of the P-EXS exceeded our patency
rates, it performed worse compared to externally supported
PTFE.16
The patency results of our P-non-EXS cohort were also
somewhat disappointing. Two other recent randomised
controlled trials, implanting non-EXS polyester prostheses,
showed 2-year primary patency results of 70%.4,19 The only
randomised controlled trial that also used the knitted
polyester (Fluoropassiv) prosthesis (P-non-EXS), noted 1-
year primary and secondary patency rates of 36% and 49%.
Two-year primary and secondary patency rates were 36%
and 46%, respectively.20 Compared to our trial these re-
ported patency results were even lower (Tables 3e5).Table 3. Life table primary patency.
Interval (mo) No. at risk at
beginning of
interval
No. failed
during interval
P-EXS
0e3 136 19
3e6 116 10
6e9 105 17
9e12 82 0
12e15 82 16
15e18 64 0
18e21 64 9
21e24 53 0
P-non-EXS
0e3 129 3
3e6 121 18
6e9 98 8
9e12 90 0
12e15 89 13
15e18 76 0
18e21 76 3
21e24 71 0We cannot fully explain why our patency rates of P-EXS
were signiﬁcantly worse compared to P-non-EXS. It is possible
that the ringed prosthesis is less ﬂexible. It can actually
increase the tendency to kink at the junction between the
ringed and non-ringed portion of the graft instead of its non-
kinking property.18 It is also possible that due to a difference
in behaviour between the textile ﬁxed to the external support
and the textile free of the external support areas of high
stress occur responsible for rupture of the textile and
secondary disruption of the prosthesis.21 Post-operative
angiography showed that graft kinking and constriction still
arise in coiled supported polyester thus external support of
grafts with rings or other conﬁgurations does not necessarily
prevent graft kinking, compression and reduced ﬂow.22
In addition, the ﬁxation of the external support on the
textile could have been responsible of differences on tissue
inﬁltration and healing between areas with and without
support. It could also be responsible for differences of
mechanical behaviour of the textile at the junction leading to
tears of the luminal ﬁbrin coverage of the prosthesis and
promote thrombogenicity. This drawback could possibly
counteract the advantages of the kink and compression
resistance and explain our poorer results in areas that were
not exposed to major kinks or compression.
Another explanation could be the post-operative dilata-
tion of all polyester grafts once implanted, which seems to
happen immediately post-operatively after clamp release.
While 6 mm non-supported polyester grafts dilate to
approximately 7.2 mm (þ20%), externally supported grafts
do not dilatate due to the external support. Several studies
found better patency rates for larger grafts.23,24 This effect
may have inﬂuenced or biased this study as the non-sup-
ported grafts may have had an actual better ﬂow, which can
explain the better patency rates.
Fluoropassiv is a polyester graft with a surface covered
with ﬂuoropolymer molecules bonding with the polyesterWithdrawn
during interval
Cumulative
patency rate (%)
Standard error
(%)
1 86 3
1 79 4
6 65 4
0 65 4
2 53 4
0 53 4
2 45 4
0 45 4
5 98 1
5 83 3
0 76 4
1 76 4
0 65 4
0 65 4
2 62 4
0 62 4
Table 5. Life table secondary patency.
Interval (mo) No. at risk at
beginning of
interval
No. failed
during interval
Withdrawn
during interval
Cumulative
patency rate (%)
Standard error
(%)
P-EXS
0e3 136 2 1 99 1
3e6 133 9 1 92 2
6e9 123 10 6 84 3
9e12 107 0 0 84 3
12e15 107 10 4 76 4
15e18 93 0 0 76 4
18e21 93 7 3 70 4
21e24 83 0 0 70 4
P-non-EXS
0e3 129 1 5 99 1
3e6 123 8 5 93 2
6e9 110 5 0 88 3
9e12 105 0 1 88 3
12e15 104 4 0 85 3
15e18 100 0 0 85 3
18e21 100 1 3 84 3
21e24 96 0 0 84 3
Table 4. Life table primary assisted patency.
Interval (mo) No. at risk at
beginning of
interval
No. failed
during interval
Withdrawn
during interval
Cumulative
patency rate (%)
Standard error
(%)
P-EXS
0e3 136 16 1 88 3
3e6 119 12 1 79 3
6e9 106 12 6 70 4
9e12 88 0 0 70 4
12e15 88 10 3 62 4
15e18 75 0 0 62 4
18e21 75 6 2 57 4
21e24 67 0 0 57 4
P-non-EXS
0e3 129 3 5 98 1
3e6 121 11 5 89 3
6e9 105 8 0 82 4
9e12 97 0 1 82 4
12e15 96 4 0 78 4
15e18 92 0 0 78 4
18e21 92 4 3 75 4
21e24 85 0 0 75 4
280 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 3 March/2013giving an interpenetrating molecular network at the interface
between the twopolymers.The result is a newbiomaterialwith
a supposed lower thrombogenicity. However, both P-EXS and
P-non-EXS showed unsatisfactory patency results compared to
other polyester prostheses. The reason for the early throm-
bosis in the knitted polyester prosthesis is unknown.
This study is the ﬁrst randomised controlled trial in which
externally supported knitted polyester for femoro-popliteal
AK bypass grafting was compared to externally unsupported
knitted polyester. The patency results of the P-EXS cohort
were inferior to the P-non-EXS cohort.Based on our results we see no beneﬁt of external support
in 6 mm polyester AK femoro-popliteal bypass grafts, and
therefore unsupported grafts may be used as well.
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